J
Joseph M. Pilewski
Researcher at University of Pittsburgh
Publications - 322
Citations - 17263
Joseph M. Pilewski is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Lung transplantation & Cystic fibrosis. The author has an hindex of 65, co-authored 285 publications receiving 15142 citations. Previous affiliations of Joseph M. Pilewski include Boston Children's Hospital & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes
Maria M. Crespo,Christian Bermudez,Mary Amanda Dew,B.A. Johnson,M. Patricia George,Jay K. Bhama,Matthew R. Morrell,Jonathan D'Cunha,Norihisa Shigemura,Thomas J. Richards,Joseph M. Pilewski +10 more
TL;DR: The findings that 1- and 5-year survival rates of Patients with scleroderma were similar to those of patients with pulmonary fibrosis indicate that lung transplant is a reasonable treatment option in selected patients with s cleroderma.
Journal ArticleDOI
Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis
Mike M. Myerburg,Erin E. McKenna,Cliff J. Luke,Raymond A. Frizzell,Thomas R. Kleyman,Joseph M. Pilewski +5 more
TL;DR: It is suggested that a proteolytic cascade involving prostasin, an upstream prostasin-activating protease, and PN-1 regulate Na+ absorption in the airway and that abnormal prostasin expression contributes to excessive proteolytics activation of ENaC in CF patients.
Journal ArticleDOI
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells
Mike M. Myerburg,Joseph D. Latoche,Erin E. McKenna,Laura P. Stabile,Jill S. Siegfried,Carol Feghali-Bostwick,Joseph M. Pilewski +6 more
TL;DR: These results provide a model to study fibroblast modulation of epithelial phenotype and indicate that HGF secreted by subepithelial fibroblasts contributes to HBE cell differentiation.
Journal ArticleDOI
Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings.
Christopher R. Ensor,Samuel A. Yousem,Marilyn Marrari,Matthew R. Morrell,Massimo Mangiola,Joseph M. Pilewski,Jonathan D'Cunha,Stephen R. Wisniewski,Raman Venkataramanan,Adriana Zeevi,John F. McDyer +10 more
TL;DR: Responses to CFZ had less chronic lung allograft dysfunction or progression versus nonresponders and larger prospective interventional studies are needed to further describe the benefit of CFZ‐based therapy for pulmonary AMR.
Journal ArticleDOI
Multisite comparison of mucociliary and cough clearance measures using standardized methods
William D. Bennett,Beth L. Laube,Timothy E. Corcoran,Kirby L. Zeman,Gail Sharpless,Kristina Thomas,Jihong Wu,Peter J. Mogayzel,Joseph M. Pilewski,Scott H. Donaldson +9 more
TL;DR: This standardized protocol may prove beneficial in multicenter trials for testing new therapies that are designed to improve MCC/CC and a multivariate analysis of clearance versus time with site and C/P as covariates showed no significant site-specific differences.